Scopio Labs Ltd.

Based in Israel, Scopio Labs Ltd. develops advanced digital cell morphology solutions that enhance diagnostic capabilities in hematology labs through innovative imaging platforms. Founded in 2015 and headquartered in Tel Aviv, Israel, Scopio Labs Ltd. specializes in digital imaging solutions for healthcare, particularly in hematology.

In July 2025, Scopio Labs Ltd. raised USD 10 million in series D funding led by new investor Viola Goup. The CEO of the company is Itai Hayut. Scopio Labs specializes in advanced digital cell morphology solutions, primarily through its core products, the Scopio X100 and Scopio X100HT imaging platforms.

These devices utilize computational photography and artificial intelligence to provide high-resolution images of cell samples, such as peripheral blood smears and bone marrow aspirates. The Scopio X100 is designed for small to medium-sized labs, while the X100HT is tailored for high-throughput environments, both aimed at enabling comprehensive analyses in hematology labs without traditional microscopy methods. Their products serve healthcare facilities, including hospitals and diagnostic labs across North America, Europe, and Asia, addressing the need for efficient and accurate diagnostics. Scopio Labs generates revenue primarily through direct sales of its imaging platforms and associated software solutions to healthcare facilities.

The sales structure typically includes direct sales and potential subscription models for software updates and AI analytics services. Their flagship products, Scopio X100 and X100HT, are procured by hematology labs and hospitals as part of efforts to digitize and enhance diagnostic workflows. Revenue is bolstered by partnerships with organizations like Beckman Coulter, facilitating access to digital imaging and analysis capabilities. The company plans to utilize the July 2025 funding to accelerate its automated blood morphology technology.